Abstract: A hybrid switch apparatus includes a gate drive circuit producing a gate drive signal, a GaN high electron mobility transistor (HEMT) having a first gate, a first drain, and a first source. A silicon (Si) MOSFET has a second gate, a second drain, and a second source. The GaN HEMT and the Si MOSFET are connected in a parallel arrangement so that (i) the first drain and the second drain are electrically connected and (ii) the first source and the second source are electrically connected. The second gate is connected to the gate drive circuit output to receive the gate drive signal. A delay block has an input connected to the gate drive circuit output and an delay block output is configured to produce a delayed gate drive signal for driving the GaN HEMT.

Abstract: An AC/DC conversion apparatus includes first, second, and third AC/DC conversion modules operated by a controller in two modes of operation. In the first mode, the input AC signal is 3-phase and each of the three modules are enabled to handle a respective one of the input phases. In the second mode, the input AC signal is single phase and the first and second modules are enabled to deliver output power based on the single-phase AC input, while the controller actuates an H-bridge switches in the third module to which active filter circuitry is connected, to reduce an AC component in the output signal. The active filter circuitry can be selectively connected to the H-bridge switches when single-phase operation is desired, which circuitry may be disposed in a filter housing having male electrical terminals that cooperate with corresponding female terminals associated with the third module.

Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.

Abstract: A sixteen-membered macrolide compound and use thereof, the compound structure being represented in formula (I), wherein R is CH3 or C2H5. The present compound has a wide range of application in the preparation of chemicals for preventing and controlling insect pests and mites of agriculture and forestry.

Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.

Abstract: Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production.

Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.

Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.

Abstract: A system, device, and method for receiving, preparing and identifying a biological sample. Some parts may be user held and actuated. The sample may be detected by an array of sensors. The system may comprise reusable and disposable components arranged to be connected together. The biological sample may contain nucleic acids, proteins, or other molecules to be detected.

Abstract: The present invention relates to a process of a chemically synthetic drug, and in particular, to a new intermediate of a heparin pentasaccharide and a preparation method thereof. The process has high reaction efficiency, and an easy reaction operation. The reaction intermediate is easy to be purified, and is appropriate for an industrialization production.

Abstract: In one embodiment, a bidirectional DC/DC converter includes a DC/AC inverter having active switches (e.g., MOSFETs), and an AC/DC rectifier having a capacitor that performs DC-bias current blocking and active switches (e.g., MOSFETs) arranged in a bridge configuration. A microcontroller is coupled to the active switches of the DC/AC inverter and AC/DC rectifier and configured to provide control signals thereto according to a control algorithm that, when power is to flow in a forward direction, sends control signals to operate the active switches of the DC/AC inverter at a duty cycle and to disable the active switches of the AC/DC rectifier, and when power is to flow in a reverse direction, sends control signals to operate the active switches of the DC/AC inverter to disable the active switches of the DC/AC inverter and operates the active switches of the AC/DC rectifier at a duty cycle.

Abstract: In one embodiment, a bidirectional battery charger integrated with renewable energy generation includes a primary side AC/DC rectifier coupled to the electrical grid and a first DC bus, a DC/AC inverter coupled to the first DC bus and a primary winding, a secondary side AC/DC rectifier coupled to a secondary winding and a battery, and a boost converter coupled to a renewable energy generator and the first DC bus. The boost converter includes an active switch controlled by a control algorithm that, when renewable power is available, operates the active switch at a duty cycle that allows power to flow from the renewable energy generator to the first DC bus and on to charge the battery (without passing though the primary side AC/DC rectifier) or on to supply the electrical grid (without passing through the DC/AC inverter and secondary side AC/DC rectifier), and, when not available, disables the active switch.

Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.

Abstract: The hardness of zinc sulfide is increased by adding selective elements within a specified range to the crystal lattice of the zinc sulfide. The increased hardness over conventional zinc sulfide does not substantially compromise the optical properties of the zinc sulfide. The zinc sulfide may be used as a protective coating for windows and domes.

Abstract: The hardness of zinc sulfide is increased by adding selective elements within a specified range to the crystal lattice of the zinc sulfide. The increased hardness over conventional zinc sulfide does not substantially compromise the optical properties of the zinc sulfide. The zinc sulfide may be used as a protective coating for windows and domes.

Abstract: The present invention relates to a recombinant microorganism expressing avermectin or analogues thereof and construction method thereof, and also relates to a method of producing avermectin or analogues thereof using the recombinant microorganism, and avermectin or analogues thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogues thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogues thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.

Abstract: A single-phase AC/DC electric power conversion apparatus includes an indirect matrix converter having an input interface to receive a first alternating current (AC) signal and an output interface to produce a second AC signal, where the first AC signal has a grid frequency. A transformer has a primary winding and an electrically isolated and magnetically coupled secondary winding. A coupling inductor is connected in series between the output interface of the indirect matrix converter and the primary winding. An H-bridge switching arrangement is connected to the secondary winding and produces an output signal having a DC component and at least one AC component. The at least one AC component has a second order harmonic of the grid frequency. An active filter reduces the second order harmonic AC component. A modular conversion apparatus for three-phase power replicates the single-phase apparatus as a module for each phase and omits the active filter.

Abstract: The present invention provides adiabatic plug flow reactors suitable for the production of chlorinated and/or fluorinated propene and higher alkenes from the reaction of chlorinated and/or fluorinated alkanes and chlorinated and/or fluorinated alkenes. The reactors comprise one or more designs that minimize the production of by-products at a desired conversion.

Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.

Abstract: A driver circuit has a gate drive terminal that produces a gate drive signal to control paralleled power semiconductor switches, such as GaN high electron mobility transistor (HEMT) devices. One of the switches is closest to the gate drive terminal such that its gate drive loop inductance is smaller than the remaining switches that are farther away having a larger loop inductance. An additional resistor or gate-source capacitor is provided in the gate drive circuit of the closest switch which increases the total gate resistance of the closest switch compared to the remaining switches, which delays the turn off time of the closest switch. The delay permits zero voltage switching turn-off of the remaining switches to reduce noise. The closest switch is hard switched off but has the smallest loop inductance, which allows optimized turn off.